Cyclacel Announces Abstract Selected for Presentation at

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cyclacel Announces Abstract Selected for Presentation at Society of Hematologic Oncology Annual Meeting

BERKELEY HEIGHTS, N.J., Sept. 10, 2014 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC ) (Nasdaq: CYCCP ) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced that an abstract highlighting the therapeutic potential of CYC065, the Company's novel, orally available, second generation cyclin-dependent kinase (CDK) inhibitor, in acute myeloid leukaemia (AML) and mixed-lineage leukaemia (MLL), has been selected for presentation at the Society of Hematologic Oncology (SOHO) annual meeting, taking place September 17-20, 2014 at the Hilton Americas Hotel in Houston, Texas.

Details for the presentation are as follows:

Abstract: 140
Poster: 209
Title: CYC065, potential therapeutic agent for AML and MLL leukemia
Date/Time: Wednesday, September 17th, 2014, 6:00 PM - 9:00 PM
Location: Ballroom of the Americas DE on Level 2 of the Hilton Americas Hotel
Session Title:  Acute Myeloid Leukemia
Authors:  S. Frame, C. Saladino, S. Davis, D. Blake & D. Zheleva

The abstract can be accessed through the SOHO website, www.sohoonline.org . Please note that according to SOHO policy, all data are embargoed until the time of the beginning of the presentation.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sapacitabine, Cyclacel's most advanced product candidate, is the subject of SEAMLESS, a Phase 3 trial being conducted under an SPA with the FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly, and other studies for myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL) and solid tumors including breast, lung, ovarian and pancreatic cancer and in particular those carrying gBRCA mutations. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.

Forward-looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov . Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

© Copyright 2014 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel ® are trademarks of Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc. Company: Paul McBarron, (908) 517-7330, Investor Relations/Media: Russo Partners LLC, Robert Flamm, (212) 845-4226,

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 59

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Mars Moves on Cash Tender Offers for Seniors' Notes

Updated Category News Views 104

A Strategic Financial Maneuver or a Casual Gambit? Okay, what’s Mars up to now, you ask? Here we go with this. The behemoth behind some of your favorite snacks and pet indulgences is making waves—not with candy, but with cash. Mars, Incorporated is rolling out tender offers to buy back a substantial chunk of its Senior Notes for $2 billion in cold, hard cash. When a...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 123

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
MoneyGram and Solflare Boost Crypto Cash-Out Options

Updated Category News Views 116

Crypto Meets Cash: A New Partnership in Money Movement Here's something to chew over your morning joe: MoneyGram's stepping up its game in the crypto world. They're pairing up with Solflare to let folks convert their USDC into hard cash across 170 countries and territories—no fees until New Year's Eve. It's like crypto's getting a passport to the physical world and not...

Continue Reading
Daymond John's Four-Center Bet on Longevity Game

Updated Category News Views 66

A Shark's Dive into Longevity Here you go—Daymond John, the face of FUBU and a household name from Shark Tank, is not just talking about living longer; he's putting his wallet where his words are. John is jumping into the longevity game with both feet, joining Ultimate Longevity Center's (ULC) latest venture. We're talking about four new centers across California,...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 142

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Sinch Appoints Jonas Dahlberg as New CEO: A Strategic Move

Updated Category News Views 47

A Change at the Helm: Dahlberg Takes Charge Here we go, folks—Sinch, that global powerhouse in customer communications, just got itself a new captain. Jonas Dahlberg is now officially the CEO, after warming the acting CEO seat since June. This ain't your ordinary office shuffle. It's a calculated chess move in the high-stakes tech world. Dahlberg's Path to the Top This...

Continue Reading
Trades Workforce Shortage Costs Wallop U.S. Economy

Updated Category News Views 113

The Forgotten Backbone of America Don't sleep on this: America's got itself a trade worker crisis, and it's not just a numerical hiccup. We’re down nearly 1.9 million skilled trades workers, and that's a gut punch to the economy—a hefty $1.2 billion a day in GDP loss. These are the folks who keep the wheels greased, the lights on, and the goods flowing. Without them,...

Continue Reading
Alliance for Women in Media Champions Change in 2026

Updated Category News Views 76

A Celebration of Trailblazing Women in Media If there's one thing I've learned about strong leadership, it's that you can't fake authenticity. Today, we're tipping our hats to some genuine trailblazers. The Alliance for Women in Media (AWM) held its annual Gracies Leadership Awards, celebrating the achievements and vision of seven remarkable women. Honoring the...

Continue Reading
Webull Faces FINRA Fine and Legal Battle Ahead

Updated Category News Views 100

Webull's Compliance Headache Webull’s been knocked around again. This time, the Financial Industry Regulatory Authority (FINRA) slapped it with a hefty $4.2 million fine. Talk about a hit to the wallet! It all boils down to them failing to roll out some basic anti-money laundering (AML) and other crucial compliance programs. This is no small oversight, and it's got...

Continue Reading

Top 5 Most Recently Viewed Articles

South32 Secures Key Environmental Approval for Worsley Mine

Updated Category News Views 283

South32's Worsley Mine Project Receives Environmental Approval Perth-based South32 (ASX / LSE / JSE: S32; OTC: SOUHY), an Australian leader in mining and metals, has recently obtained essential state environmental approval for its Worsley Mine Development Project. This significant milestone brings the company a step closer to accessing necessary bauxite resources, vital...

Continue Reading
Tesla's Future Beyond EVs: The Rise of AI, Robotics, and Robotaxis

Updated Category News Views 471

Tesla's Future Beyond EVs: The Rise of AI, Robotics, and Robotaxis Tesla Inc. (NASDAQ:TSLA) is trading near $418.02, showcasing a remarkable market cap of $1.31 trillion and a P/E ratio of 279.5. This impressive valuation not only underscores the innovation premium associated with Tesla but also reflects the intense valuation pressures it faces. The company has...

Continue Reading
Smartkem Showcases Innovative Display Technology at TechBlick

Updated Category News Views 44

Smartkem Set to Exhibit at TechBlick: A Spotlight on Future Electronics Smartkem, Inc. (NASDAQ: SMTK), a leader in transformative display technologies, is gearing up to showcase its innovative offerings at an upcoming global conference centered on electronics. This event, known as TechBlick: The Future of Electronics Reshaped, will take place at the Estrel Berlin Hotel...

Continue Reading
American Rebel Light Beer: Expanding Horizons in Iowa

Updated Category News Views 170

American Rebel Light Beer Expands Distribution in Iowa American Rebel Light to be served at Knoxville Raceway and the Dingus Lounge Nashville, TN — American Rebel Holdings, Inc. (NASDAQ: AREB) proudly announces its strategic expansion into Iowa through a partnership with Mahaska Bottling Company. This important move marks a significant milestone in the Company's broader...

Continue Reading
Boys & Girls Clubs Ignite Hope with Woodlands Impact Center

Updated Category News Views 195

Boys & Girls Clubs of the Northwest Suburbs Renovate New Facility The Woodlands Impact Center is poised to play a vital role in empowering local youth by providing essential services and programs. This facility aims to support 550 students, offering after-school, summer, and daytime activities that will enrich their educational and social experiences. A Transformative...

Continue Reading